HCW Biologics entered into a Securities Purchase Agreement for a private placement of 618,682 units, generating approximately $1.6 million in gross proceeds to support working capital and clinical development. Each unit includes one common share or a pre-funded warrant, plus the right to receive a common warrant subject to stockholder approval under Nasdaq rules. Pre-funded warrants are immediately exercisable at $0.0001 per share, while common warrants, once approved and issued, will be exercisable at $2.585 for 5.5 years. The company also executed a Registration Rights Agreement, committing to file a resale registration statement within 15 trading days and seek effectiveness within 60 days.
Agreement 1: HCW Biologics Raises $1.6 Million in Private Placement; Units Priced at $2.585
- Agreement type: Securities Purchase Agreement for private placement of units
- Counterparty: Accredited investors
- Signed / Effective: Jul 29 2026 / same
- Duration / Termination: At will
- Reason: Raise working capital and fund clinical development
Agreement 2: HCW Biologics Grants Investors Registration Rights for Resale of Shares and Warrants
- Agreement type: Registration Rights Agreement
- Counterparty: Accredited investors
- Signed / Effective: Jul 29 2026 / same
- Duration / Termination: At will
- Reason: Enable liquidity for investors from private placement
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.